Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01QML
|
||||
| Former ID |
DAP000846
|
||||
| Drug Name |
Carphenazine
|
||||
| Synonyms |
Carfenazine; Carphenazin; Procethazine; Proketazin; Carfenazina [INN-Spanish]; Carfenazine [INN:BAN]; Carfenazinum [INN-Latin]; 1-(10-(3-(4-(2-Hydroxyethyl)-1-piperazinyl)propyl)phenothiazin-2-yl)-1-propanone; 1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one; 1-[10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]phenothiazin-2-yl]propan-1-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Insomnia [ICD9: 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F51.0, G47.0] | Approved | [1] | ||
| Schizophrenia [ICD9: 295; ICD10:F20] | Withdrawn from market | [2], [3] | |||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Wyeth Ayerst Laboratories
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H31N3O2S
|
||||
| InChI |
InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3
|
||||
| InChIKey |
XZSMZRXAEFNJCU-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 2622-30-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| ChEBI ID |
ChEBI:51235
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [4], [5] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7140). | ||||
| REF 3 | Drug information of Carphenazine, 2008. eduDrugs. | ||||
| REF 4 | Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. | ||||
| REF 5 | Comparison of dosage ranges of carphenazine and trifluoperazine in elderly chronic schizophrenics. Dis Nerv Syst. 1968 Oct;29(10):695-7. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.